ArticleCureus2025
Holistic Management of Multiple Myeloma: A Case Report on Siddha Therapy as an Adjunct to the Bortezomib-Lenalidomide-Dexamethasone (BLD) Regimen.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a complex haematological malignancy characterized by the clonal proliferation of plasma cells within the bone marrow. It is the second most common haematological malignancy that presents in elderly patients. The integration of complementary medicine into conventional cancer care is increasingly observed among patients, driven by factors such as symptom management, holistic well-being, and cultural alignment. This case report presents the integrated management of a 65-year-old male patient diagnosed with MM, who received both chemotherapy and Siddha medicine to alleviate constitutional symptoms and improve overall well-being. The patient complained of weakness, easy fatigability, and insomnia. The diagnosis of MM was established elsewhere through serum protein electrophoresis, immunofixation, and bone marrow biopsy. He was treated with the bortezomib, lenalidomide, and dexamethasone (BLD) regimen along with a combination of Siddha herbal and herbo-mineral formulations. After six months, the patient demonstrated significant improvements in haematological parameters, general physical condition, and quality of life. This case highlights the potential benefits of integrating traditional Siddha medicine with conventional allopathic therapy in managing MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.